Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.

In individuals without diabetes, it quickly became the most commonly used weight-loss medication, surpassing semaglutide ... s FDA approval for weight management. 2 Longer-term data on this ...

At the heart of the Prime protocol is Kyzatrex™, an FDA-approved oral testosterone ... which uses the popular compound, Semaglutide, targets the booming weight-loss market.

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Novo Nordisk (NYSE:NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy ... reporting positive Phase 3 trial data showing the pill helped patients ...

At the heart of the Prime protocol is Kyzatrex, an FDA-approved oral testosterone ... which uses the popular compound, Semaglutide, targets the booming weight-loss market. How does Slim by MangoRx ...

Novo Nordisk (NYSE:NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss ... 3 trial data showing the pill helped patients lose up to 15% of their body weight over 64 ...